Holen Sie sich die Stockscreener-App
0.9288
0.00%
0.00
Handel nachbörslich:
.93
0.0012
+0.13%
Schlusskurs vom Vortag:
$0.9288
Offen:
$0.9389
24-Stunden-Volumen:
559
Relative Volume:
33.03
Marktkapitalisierung:
$N/A
Einnahmen:
-
Nettoeinkommen (Verlust:
$-22.01M
KGV:
-0.0109
EPS:
-85.4
Netto-Cashflow:
$-18.31M
1W Leistung:
-3.36%
1M Leistung:
-69.06%
6M Leistung:
-81.55%
1J Leistung:
-88.61%
1-Tages-Spanne:
$0.9288
$0.9389
1-Wochen-Bereich:
$0.9288
$0.9389
52-Wochen-Spanne:
$0.9288
$0.9389
Vaccinex Inc Stock (VCNX) Company Profile
Vergleichen Sie VCNX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VCNX
Vaccinex Inc
|
0.9288 | 0 | 0 | -22.01M | -18.31M | -85.40 |
|
ONC
Beigene Ltd Adr
|
240.41 | 25.57B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.10 | 111.79B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 39.90M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.85 | 65.28B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
73.93 | 6.31B | 0 | -153.72M | -103.81M | -2.00 |
Vaccinex Inc Stock (VCNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-09-23 | Herabstufung | BTIG Research | Buy → Neutral |
| 2018-09-04 | Eingeleitet | Ladenburg Thalmann | Buy |
Vaccinex Inc Aktie (VCNX) Neueste Nachrichten
Vaccinex presents promising cancer treatment data at ASCO By Investing.com - Investing.com India
Vaccinex presents promising cancer treatment data at ASCO - Investing.com
Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting | VCNX Stock News - GuruFocus
Vaccinex, Inc. to Present New Data on Pepinemab's Role in Enhancing Immune Responses in Head and Neck Cancer at ASCO 2025 - Nasdaq
Vaccinex to Report Promising New Clinical Results of - GlobeNewswire
Clinical Trial Success: New Drug Transforms Cold Tumors into Hot Immune Centers in Head and Neck Cancer - Stock Titan
Vaccinex (NASDAQ:VCNX) Stock Price Down 11.3% – Here’s What Happened - Defense World
AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug Targets - ACCESS Newswire
Vaccinex (NASDAQ:VCNX) Trading 9.9% Higher – Still a Buy? - Defense World
Vaccinex reports pepinemab boosts immune response in cancer By Investing.com - Investing.com South Africa
Vaccinex (VCNX) Presents New Findings on Pepinemab for Cancer Tr - GuruFocus
Vaccinex to Report Promising New Clinical Data Revealing Pepinem - GuruFocus
Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR) | VCNX Stock News - GuruFocus
Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR) - The Manila Times
Vaccinex reports pepinemab boosts immune response in cancer - Investing.com Australia
Vaccinex, Inc. Announces Promising Data on Pepinemab as Neoadjuvant Immunotherapy in Metastatic Melanoma and Head and Neck Cancer at AACR 2025 - Nasdaq
Vaccinex to Report Promising New Clinical Data Revealing - GlobeNewswire
VACCINEX, INC. SEC 10-K Report - TradingView
Pre-market Movers In Healthcare Sector: CTXR, VCNX, SRNE, ITRM, RWLK… - RTTNews
Osteosarcoma Market Set for Groundbreaking Expansion by 2032, Forecasts DelveInsight | Aurora Biopharma, BioAtla, Iovance Biotherapeutics, Isofol Medical AB, Bristol-Myers Squibb, Cellestia Biotech - The Globe and Mail
Vaccinex Delays Yearly Report Filing - TipRanks
Vaccinex director resigns, no disagreement cited By Investing.com - Investing.com South Africa
Vaccinex director resigns, no disagreement cited - Investing.com India
Stocks in play: Neo Performance Materials Inc. - The Globe and Mail
Finance Watch: Sutro Halves Workforce, Cuts Lead ADC And CEO Moves On - Citeline News & Insights
Vaccinex plans Nasdaq exit as Alzheimer market pressure grows - Yahoo Finance
Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market - GlobeNewswire
Can Vaccinex Survive After Nasdaq Exit? Key Details on Company's Future Strategy - StockTitan
Vaccinex Stock Price, Quotes and Forecasts | OTC:VCNX - Benzinga
Vaccinex (NASDAQ:VCNX) Stock Price Down 3.7% – Time to Sell? - Defense World
Alzheimer's Disease Clinical Trial Pipeline | 110+ Companies Pioneering Breakthroughs in Treatment | - EIN News
RFK Jr. says he's resigned from anti-vaccine nonprofit as he seeks nation's top health official job - AP News
Vaccinex (NASDAQ:VCNX) Stock Price Down 3.4% – What’s Next? - Defense World
Louisiana forbids public health workers from promoting COVID, flu and mpox shots : ShotsHealth News - NPR
Vaccinex Stock to Be Delisted From Nasdaq - Marketscreener.com
Vaccinex Faces Delisting from Nasdaq, Details Plans for OTC Quotation - Defense World
Vaccinex to be delisted from Nasdaq over equity shortfall By Investing.com - Investing.com South Africa
United States shares lower at close of trade; Dow Jones Industrial Average down 0.61% - Investing.com India
Vaccinex to be delisted from Nasdaq over equity shortfall - Investing.com India
Vaccinex Shares Tumble 63% On Nasdaq Delisting - MarketWatch
Vaccinex Faces Nasdaq Delisting Amid Financial Struggles; Shares Drop 62% - Yahoo Finance
Vaccinex stock plunges to 52-week low at $1.36 amid market challenges - Investing.com
Vaccinex receives delisting notice from Nasdaq, shares down over 49% - MSN
Vaccinex Announces Receipt of Delisting Notification from Nasdaq - The Manila Times
Finanzdaten der Vaccinex Inc-Aktie (VCNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
8.70%
1.64%
Kapitalisierung:
|
Volumen (24h):